Your browser doesn't support javascript.
loading
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching.
Moreau, Philippe; Hulin, Cyrille; Zweegman, Sonja; Hashim, Mahmoud; Hu, Yannan; Heeg, Bart; de Boer, Carla; Vanquickelberghe, Veronique; Kampfenkel, Tobias; He, Jianming; Lam, Annette; Cote, Sarah; Sonneveld, Pieter.
Afiliação
  • Moreau P; Nantes University Hospital Hôtel-Dieu Nantes France.
  • Hulin C; Hospital Center University De Bordeaux Bordeaux France.
  • Zweegman S; Amsterdam UMC, Vrije Universiteit Amsterdam Cancer Center Amsterdam Amsterdam The Netherlands.
  • Hashim M; Ingress Health Rotterdam The Netherlands.
  • Hu Y; Ingress Health Rotterdam The Netherlands.
  • Heeg B; Ingress Health Rotterdam The Netherlands.
  • de Boer C; Janssen Research & Development Leiden The Netherlands.
  • Vanquickelberghe V; Janssen Research & Development Beerse Belgium.
  • Kampfenkel T; Janssen Research & Development Leiden The Netherlands.
  • He J; Janssen Global Services LLC Raritan New Jersey USA.
  • Lam A; Janssen Global Services LLC Raritan New Jersey USA.
  • Cote S; Janssen Global Services LLC Raritan New Jersey USA.
  • Sonneveld P; Erasmus MC Cancer Institute Rotterdam The Netherlands.
EJHaem ; 2(1): 66-80, 2021 Feb.
Article em En | MEDLINE | ID: mdl-35846097
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article